Brain glucose metabolism heterogeneity in idiopathic REM sleep behavior disorder and in Parkinson's disease

Dario Arnaldi (Corresponding author), Sanne K. Meles, Alessandro Giuliani, Silvia Morbelli, Remco J. Renken, Annette Janzen, Elisabeth Sittig-Wiegand, Candan Depboylu, Kathrin Reetz, Sebastiaan Overeem, Angelique Pijpers, Fransje E. Reesink, Teus Van Laar, Laura K. Teune, Helmut Höffken, Marcus Luster, Lars Timmermann, Karl Kesper, Sofie M. Adriaanse, Jan BooijGianmario Sambuceti, Nicola Girtler

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

6 Citaten (Scopus)
1 Downloads (Pure)


Background/Objective: Idiopathic REM sleep behavior disorder (iRBD) often precedes Parkinson's disease (PD) and other alpha-synucleinopathies. The aim of the study is to investigate brain glucose metabolism of patients with RBD and PD by means of a multidimensional scaling approach, using18F-FDG-PET as a biomarker of synaptic function. Methods: Thirty-six iRBD patients (64.1±6.5 y, 32 M), 72 PD patients, and 79 controls (65.6±9.4 y, 53 M) underwent brain 18 F-FDG-PET. PD patients were divided according to the absence (PD, 32 subjects; 68.4±8.5 y, 15 M) or presence (PDRBD, 40 subjects; 71.8±6.6 y, 29 M) of RBD. 18F-FDG-PET scans were used to independently discriminate subjects belonging to four categories: Controls (RBD no, PD no), iRBD (RBD yes, PD no), PD (RBD no, PD yes) and PDRBD (RBD yes, PD yes). Results: The discriminant analysis was moderately accurate in identifying the correct category. This is because the model mostly confounds iRBD and PD, thus the intermediate classes. Indeed, iRBD, PD and PDRBD were progressively located at increasing distance from controls and are ordered along a single dimension (principal coordinate analysis) indicating the presence of a single flux of variation encompassing both RBD and PD conditions. Conclusion: Data-driven approach to brain 18 F-FDG-PET showed only moderate discrimination between iRBD and PD patients, highlighting brain glucose metabolism heterogeneity among such patients. iRBD should be considered as a marker of an ongoing condition that may be picked-up in different stages across patients and thus express different brain imaging features and likely different clinical trajectories.

Originele taal-2Engels
Pagina's (van-tot)229-239
Aantal pagina's11
TijdschriftJournal of Parkinson's Disease
Nummer van het tijdschrift1
StatusGepubliceerd - 1 jan 2019

Citeer dit